Silexion reports first patient dosed in SIL204 Phase 2/3 pancreatic cancer trial
Silexion Therapeutics Corp announced the first patient has been successfully dosed in a global Phase 2/3 trial of the RNAi therapy SIL204 for locally advanced pancreatic cancer, marking a key operational milestone.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed